Dermot O'Toole

Dermot O'Toole

Auto-generated profile, based on publicly available information

Dermot O'Toole

Department of Clinical Medicine, St James Hospital, Trinity College Dublin & National Centre for Neuroendocrine Tumours, St Vincent's University Hospital, Dublin, Ireland

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2009 in Neuroendocrinology
Verified
Journal Article
Closed access
PDF file
DODermot O’tOole
Dermot O’tOole
AGAshley Grossman
Ashley Grossman
DGDavid Gross
David Gross
GFGianfranco Delle Fave
Gianfranco Delle Fave
JBJaroslava Barkmanova
Jaroslava Barkmanova
UPUrsula Plöckinger
Ursula Plöckinger


30 November 2017 in Clinical Endoscopy
Verified
Journal Article
Open access
PDF file
JCJun Liong Chin
Jun Liong Chin
DODermot O’tOole
Dermot O’tOole
- What should we do next?

1 December 2020 in Digestive Surgery
Verified
Journal Article
Closed access
PDF file
JCJun Liong Chin
Jun Liong Chin
JOJim O’cOnnell
Jim O’cOnnell
CMCian Muldoon
Cian Muldoon
NSNiall Swan
Niall Swan
JRJohn Vincent Reynolds
John Vincent Reynolds
DODermot O’tOole
Dermot O’tOole
Background: Current guidance for type 1 gastric neuroendocrine neoplasms (gNENs) recommends either resection of all visible lesions or selective resection of gNENs >10 mm. We adopt a selective strategy targeting lesions approaching 10 mm for endoscopic mucosal resection (EMR) and provide surveillance for smaller lesions. Objectives: This study aimed to describe the incidence of type 1 gNENs requiring endoscopic/surgical resection and the risk of disease progression (both considered significant disease) on endoscopic surveillance. The secondary objective was to assess the risk factors for disease progression during surveillance and the incidence of gastric dysplasia/adenoma/adenocarcinoma. Methods: We collected consecutive patients with type 1 gNENs and obtained demographic and clinical data through the electronic patient record. Results: In our cohort of 57 patients, 12 patients had EMR at index gastroscopy; 7 patients had surgery (4: large/multiple gNENs and 3: nodal metastases) (5.2% [3/57] risk of nodal metastases); and a patient with nodal and liver metastases (1.8% [1/57] risk of distant metastases). The prevalence of gastric adenocarcinoma in our study was 3.5% with an incidence rate of 9.59 per 1,000 persons per year. For patients undergoing surveillance, 29.5% (13/44) of patients progressed requiring resection. Serum gastrin was significantly higher in patients who progressed to resection (p value = 0.023). Conclusion: We concluded that up to a third of patients with type 1 gNENs have significant disease requiring resection. Hence, endoscopic surveillance and resect strategy would benefit patients.

1 September 2002 in American Journal of Roentgenology
Verified
Journal Article
Closed access
ARAnne-Sophie Rangheard
Anne-Sophie Rangheard
VVValérie Vilgrain
Valérie Vilgrain
PAPascale Audet
Pascale Audet
DODermot O'Toole
Dermot O'Toole
MVMarie-Pierre Vullierme
Marie-Pierre Vullierme
YMYves Menu
Yves Menu
OBJECTIVE. The records of 10 patients with focal nodular hyperplasia inducing intrahepatic vein obstruction were reviewed. The purpose of this study was to describe and emphasize the imaging features of these findings. CONCLUSION. Focal nodular hyperplasia may be responsible for hepatic vein obstruction with hepatic vein collaterals. The relatively large size and central location of the lesions seem to play important roles in the obstruction of the hepatic veins.